News

Categories

October 9, 2025

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

September 2, 2025

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

August 19, 2025

Zymeworks Announces Participation in Upcoming Investor Conferences

August 11, 2025

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 7, 2025

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

July 28, 2025

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

July 17, 2025

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

May 30, 2025

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

May 22, 2025

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

May 21, 2025

Zymeworks Announces Participation in Upcoming Investor Conferences

May 19, 2025

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

May 8, 2025

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results